Related Experiment Video

Updated: May 24, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

[Research progress on MKP-1 in tumor drug resistance]

Yan Hai1, Xiu-wen Tang

  • 1Department of Biochemistry and Genetics, Zhejiang University School of Medicine, Hangzhou 310058 China.

Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences
|March 16, 2012
PubMed

Insights

Tumor drug resistance hinders chemotherapy. Understanding Mitogen-activated protein kinase phosphatase-1 (MKP-1) mechanisms and reversing its role in drug resistance is crucial for improving chemotherapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Context:

  • Tumor drug resistance is a major challenge in chemotherapy, limiting treatment efficacy.
  • Mitogen-activated protein kinase phosphatase-1 (MKP-1) is implicated in mediating drug resistance.
  • Existing research shows MKP-1 regulates MAPKs and is influenced by ERK and p38 pathways.

Purpose:

  • To investigate the role of MKP-1 in tumor drug resistance.
  • To explore the relationship between MKP-1 and other signaling pathways involved in drug resistance.
  • To identify potential strategies for overcoming chemotherapy resistance.

Summary:

  • Chemotherapy's effectiveness is significantly hampered by tumor drug resistance.
  • Mitogen-activated protein kinase phosphatase-1 (MKP-1), a negative regulator of MAPKs, plays a critical role in chemotherapy resistance.
  • While MKP-1's involvement with ERK and p38 pathways is known, its interaction with other resistance-related pathways requires further elucidation.

Impact:

  • Elucidating MKP-1's comprehensive role in drug resistance can pave the way for novel therapeutic strategies.
  • Understanding these mechanisms may lead to the development of drugs that can reverse or prevent chemotherapy resistance.
  • Improved chemotherapy effectiveness through overcoming drug resistance will enhance patient outcomes and survival rates.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...